Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nucana PLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, BERRY, LAYLA D. Because there is only the pending office action, the assigned official is the busiest examiner for the portfolio. The prosecution is concentrated in a distinct art unit, which means the pending matter does not face divergent procedural requirements from multiple units.
With the distinct examiner and the pending action, the company maintains a direct point of contact for its current patent office interactions. This alignment ensures that the prosecution strategy remains centralized within the Biotechnology & Pharmaceuticals sector. Practitioners can monitor the specific tendencies of BERRY, LAYLA D to anticipate the outcome of the active matter. This streamlined profile suggests that the company is focusing its resources on a specific technical advancement. The current workload represents the entirety of the company's active engagement with the examiner. The legal team can dedicate its full attention to resolving this specific office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18749420 | SYNTHESIS OF PHOSPHATE DERIVATIVES | BERRY, LAYLA D | 1693 | §103 | Non-Final OA | — | Pending | Jun 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNucana PLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Layla D Berry has the most, with 1 of Nucana PLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
